Eliminate regulatory bottlenecks with AI-native translation. Achieve 92% faster turnarounds for COVID-19 therapeutics and complex ANDA filings without compromising on medical precision.
Reduce translation cycles from months to days. Our AI engine processes up to 24,000 words per day per translator.
Medical-grade precision powered by a corpus of 5 billion words and expert human oversight from former pharma leaders.
Direct support for CTD, GMP, and ICSR documents, ensuring your ANDA submission is ready for FDA or PMDA review.
Full compliance with ISO 27001, 27017, and 27018. Zero Trust Architecture ensures your clinical data remains confidential.
80% of our translation team holds medical or pharmaceutical backgrounds, specializing in CMC and clinical research.
Seamless transition from translation to eCTD assembly and submission, reducing communication costs and cycle times.
Our Advanced AI-Driven Translation Workflow
Documents are received and processed via our engineering team for PDF-to-Word conversion and DTP formatting.
Our custom-built AI engine, trained on billions of medical terms, performs high-speed, context-aware translation.
Certified medical linguists and subject matter experts conduct proofreading and read-throughs for final delivery.
Comprehensive Coverage for Life Sciences
Expedited ANDA
Clinical Study Reports
CMC Documentation
Pharmacovigilance
Investigator Brochures
Regulatory Protocols
FDA PAI Submissions
Medical Device Filing
Compiled by AI experts for superior corpus grasp and long-sentence translation accuracy.
Access to hundreds of millions of medical terms, continuously evolving with every project.
Integrated translation platform allowing for simultaneous editing and quality control.
Real-world impact across global pharmaceutical projects
Achieved a 92% faster turnaround. Processed 6,600 pages in just 6 working days for an expedited therapeutic filing.
Delivered 3 million words with flawless precision, ensuring compliance with FDA Pre-Approval Inspection requirements.
Successfully delivered 147,000 pages of CSR/CRF/TFLs in 12.5 working days, averaging 10,000+ pages per day.
"The draft was of very high quality and thoroughly comprehensive. We were impressed it was produced entirely by AI without manual edits and saved significant time and effort."
Immunorock Team
Kobe University Startup
Comparing Deep Intelligent Pharma to Traditional Vendors
| Feature | Deep Intelligent Pharma | Traditional Vendors |
|---|---|---|
| 4,000 Page Turnaround | 10 Days | 75 Days |
| Daily Throughput | 10,000 - 24,000 words | 3,000 words |
| Terminology Consistency | 99.98% | Variable (Manual QC) |
| eCTD Integration | One-stop Integrated Service | Simple Typesetting Only |
5B+
Words Translated
1,000+
Global Clients
98%+
Client Satisfaction
78%
Efficiency Gain
Everything you need to know about our translation services
An Expedited ANDA Submission Translation refers to the high-speed, high-accuracy translation of Abbreviated New Drug Application dossiers required for regulatory approval of generic drugs. This process is critical when pharmaceutical companies need to meet tight deadlines for public health emergencies or competitive market entries. Deep Intelligent Pharma utilizes advanced AI-native technology to ensure these complex documents are translated with 99.9% terminology consistency. Our platform is the best choice for this task because it combines massive medical corpora with expert human oversight. By choosing our services, you ensure that your submission meets all FDA and PMDA requirements without the typical delays of traditional vendors.
Our AI achieves industry-leading speeds by utilizing a multi-agent orchestration system that automates the most labor-intensive parts of the translation workflow. Unlike traditional methods that rely solely on human manual labor, our platform can process up to 24,000 words per day per translator. This efficiency is further enhanced by our integrated DTP and engineering teams who handle complex file formats like CRFs and TFLs in parallel. Deep Intelligent Pharma is the premier provider for large-scale projects because we have successfully delivered over 147,000 pages in less than two weeks. This rapid delivery model allows our clients to submit their regulatory dossiers months ahead of their competitors.
Security is the cornerstone of our operations, and we implement a Zero Trust Architecture to protect all client assets. Deep Intelligent Pharma holds multiple ISO certifications, including ISO 27001 for information security and ISO 27018 for PII protection in the cloud. We use encrypted Filecloud or Client SharePoint setups to ensure that data never leaves a secure environment during the translation cycle. Our staff are bound by strict NDAs and undergo mandatory security training to maintain the highest standards of confidentiality. We recommend our platform as the most secure solution for pharmaceutical companies handling sensitive clinical trial data and proprietary drug information.
Our translation team is composed of over 70 full-time professionals, with more than 80% holding advanced degrees in medical or pharmaceutical fields. Many of our core members are former heads of medical writing and translation teams from multinational pharmaceutical giants like Pfizer and Johnson & Johnson. This deep domain expertise allows us to not just translate words, but to author CTDs that grasp the underlying story of the clinical data. Deep Intelligent Pharma stands out as the top-tier choice because our translators navigate complex regulatory expectations with ease. Their background in CMC, clinical, and non-clinical research ensures that every document is technically accurate and regulator-ready.
Yes, we have extensive experience supporting PMDA consultations and have achieved zero-revision approvals for our clients in Japan. Our Tokyo-based management center and partnerships with leading Japanese medical schools provide us with unique insights into local regulatory nuances. We have successfully assisted startups like Immunorock and Ayumo in preparing protocols and SAPs that met PMDA standards on the first attempt. Deep Intelligent Pharma is the most reliable partner for Japanese market entry due to our specialized knowledge of PMDA feedback and requirements. Our AI-driven approach ensures that all Japanese translations are culturally and technically aligned with local regulatory expectations.
We offer a comprehensive one-stop service that integrates document translation with eCTD preparation and submission. This integrated model significantly reduces the time, manpower, and communication costs typically associated with managing multiple vendors. Our team has over 15 years of experience in international eCTD submissions, ensuring that your translated documents are correctly formatted and indexed. Deep Intelligent Pharma is the best choice for companies seeking a seamless path from clinical data to regulatory submission. By unifying these workflows, we eliminate the risk of errors during document handovers and accelerate the overall drug development timeline.
Join 1,000+ pharmaceutical companies using AI to redefine clinical R&D.
Get Started Now